PRVA

Privia Health Group, Inc.

Fundamental data last updated:September 25, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Healthcare Information Services

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia. Privia Health Group, Inc. was a former subsidiary of Brighton Health Group Holdings, LLC.

 


VALUATION

P/E

123.17

Market Cap ($M USD)

$2.72B

Forward P/E

23.99

PEG

0.06

PRICE TO SALES

1.21

PRICE TO BOOK

0.00

EV / EBITDA

-7781.36

5-Year Average P/E

Free Cash Flow Yield

5.03%

DCF Value

$45.10

Graham Number

$154.67

Price to FCF

19.89

EV to FCF

-2981.43

Earnings Yield

0.81%

FCF Yield

5.03%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$0.18

Next Year EPS Growth Estimate

$0.90

Next Year Revenue Growth Estimate

$3.41B

Return on Equity (ROE)

0.01%

FREE CASH FLOW

Operating Margin

1.62%

Debt-to-Equity

0.01

Piotroski F-Score

4

Altman Z-Score

0.16

Return on Invested Capital (ROIC)

0.00%

Current Ratio

1.61

Quick Ratio

1.61

Net Debt to EBITDA

-7833.28

Interest Coverage

0.00

Gross Profit margin

9.59%

FCF PER SHARE

$1.10

REVENUE PER SHARE

$18.10

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing Privia Health Group, Inc. relative to its intrinsic value. With a DCF value significantly higher than recent pricing, there’s a clear disconnect. The Forward P/E of 25.61 suggests optimism about future earnings, yet the Altman Z-score of 0.16 raises red flags about financial distress. The earnings yield is a paltry 0.76%, indicating that the stock might not be offering enough return for the risk. Overall, while the valuation metrics suggest potential growth, the financial health indicators warrant caution.

AI Exposure / Tech Reliance

Operating in the Medical - Healthcare Information Services industry, Privia Health is well-positioned to leverage AI and modern tech advancements. The sector's inherent need for data management and analytics aligns perfectly with AI capabilities. This positioning could enhance operational efficiencies and patient outcomes, driving long-term growth.

The Bull Case

For the value or GARP investor, Privia Health presents intriguing opportunities. The forward PEG ratio of 0.06 is a standout, suggesting the stock is undervalued relative to its growth prospects. Despite a modest ROIC of 0.00%, the FCF yield of 4.71% indicates solid cash generation potential. The Piotroski F-Score of 4, while moderate, suggests some financial stability. These metrics hint at underlying pricing power and capital efficiency that could reward patient investors.

The Bear Case

However, the bear case cannot be ignored. The Price/Book ratio of 0.0038 and Price/Sales of 1.29 might seem attractive, but the EV to EBITDA is alarmingly negative, pointing to potential profitability issues. The gross profit margin of 9.59% is thin, suggesting limited pricing power. Additionally, the stock's proximity to its 52-week high could indicate technical overextension, making it vulnerable to a pullback. These structural weaknesses highlight the risks of investing in this stock.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$30.00

Institutional Ownership %

1-Year Beta

0.97

Insider Buying % (6 Mo)

Distance to 52-Week High

22.79%

Distance to 52-Week Low

13.06%

EARNINGS SURPRISE %

-75.00%

50-DAY SMA

$22.75

200-DAY SMA

$23.24

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.